To explore the efficacy of sorafenib combined with conventional therapies for refractory central nervous system leukemia, a Phase II study was conducted.
[Cancer]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Hematopoiesis News A Phase II Study of Sorafenib Combined with Conventional Therapies in Refractory...
